Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer

Experimental and Molecular Pathology

Volumn 67, Issue 3, 1999, Pages 135-143

  Williams Jr , James A ^b   Wang, Zong Ren ^a   Parrish, Rudolph S ^a   Hazlett, Linda J ^a   Smith, S Terrell ^a   Young, S Robert ^b  

^a South Carolina Cancer Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOGENETICS; ENDOMETRIUM CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ONCOGENE C MYC; ONCOGENE NEU;

EID: 0032759135     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1006/exmp.1999.2289     Document Type: Article

References (26)

1. Berchuck A., Boyd J. Molecular basis of endometrial cancer. Cancer. 76:1995;2034-2040.
2. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J. T., Dodge R., Clarke-Pearson D. L., Marks P., McKenzie S., Yin S., Bast R. C. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091.
3. Berchuck A., Rodriguez G., Keeney R. B., Soper J. T., Dodge R. K., Clarke-Pearson D. L. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstet. Gynecol. 164:1991;15-21.
4. Borst M. P., Baker V. V., Dixon D., Hatch K. D., Shingleton H. M., Miller D. M. Oncogene alterations in endometrial carcinoma. Gynecol. Oncol. 38:1990;364-366.
5. Chattopadhyay S., Marinduque B., Gilbert F. Ovarian cancer: Protocol for the preparation of banded metaphases from tumor tissue. Cancer Genet. Cytogenet. 59:1992;210-212.
6. Coussens L., Yang-Feng T. L., Liao Y.-C., Chen E., Graay A., McGrath J., Seeburg P. H., Libermann T. A., Schlessinger J., Franke U., Levinson A., Ullrich A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 230:1985;1132-1139.
7. Cox D. R., Oakes D. Analysis of Survival Data. 1984;Chapman-Hall, New York.
8. Godwin A. K., Schultz D. C., Hamilton T. C., Knudson A. G. Hoskins W. J., Perez C. A., Young R. C. Principles and Practice of Gynecologic Oncology. 1997;107-148 Lippincott-Raven, Philadelphia.
9. Hamel N. W., Sebo T. J., Wilson T. O., Keeney G. L., Roche P. C., Suman V. J. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol. Oncol. 62:1996;192-198.
10. Hetzel D. J., Wilson T. O., Keeney G. L., Roche P. C., Cha S. S., Podratz K. C. HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol. Oncol. 47:1992;179-185.
11. Inoue M., Okayama A., Fujita M., Enomoto T., Sakata M., Tanizawa O. Clinicopathological characteristics of p53 over-expression in endometrial cancers. Int. J. Cancer. 58:1994;14-19.
12. Ito K., Watanabe K., Nasim S., Sasano H., Sato S., Yajima A., Silverberg S. G., Garrett C. T. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res. 54:1994;4667-4670.
13. Kallioniemi O. P., Kallioniemi A., Kurisu W., Thor A., Chen L. C., Smith H. S. ErbB-2 amplification in breast cancer analyzed by fluorescence in-situ hybridization. Proc. Natl. Acad. Sci. USA. 89:1992;5321-5325.
14. Kaplan E. L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
15. Kohler M. F., Carney P., Dodge R., Soper J. T., Clarke-Pearson D. L., Marks J. R. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am. J. Obstet. Gynecol. 175:1996;1246-1252.
16. Landis S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 1999. Ca. Cancer J. Clin. 49:1999;8-31.
17. Lukes A. S., Kohler M. F., Pieper C. F., Kerns B. J., Bentley R., Rodriguez G. C. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer. 79:1994;2380-2385.
18. Monk B. J., Chapman J. A., Johnson G. A., Brightmen B. K., Wilczynski S. P., Schell M. J. Correlation of c-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. Am. J. Obstet. Gynecol. 171:1994;1193-1198.
19. Morrow C. P., Bundy B. N., Kurman R. J., Creasman W. T., Heller P., Homesley H. D. Relationship between risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol. 40:1991;55-65.
20. Pisani A. L., Barbuto D. A., Chen O., Ramos L., Lagasse L. D., Karlan B. Y. HER-2/neu, p53, and DNA analysis as prognosticators for survival in endometrial carcinoma. Obstet. Gynecol. 85:1995;729-734.
21. Saffari B., Jones L. A., El-Naggar A., Felix J. C., George J., Press M. F. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: Correlation with overall survival. Cancer Res. 55:1995;5693-5698.
22. Sandberg A. A. Cancer cytogenetics for clinicians. Ca. Cancer J. Clin. 44:1994;136-159.
23. Sauter G., Moch H., Moore D., Carroll P., Kerschmann R., Chew K. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 53:1993;2199-2103.
24. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
25. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Kent D. E. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
26. Zhou D., Battifora H., Yokota J., Yamamoto T., Cline M. J. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res. 47:1987;6123-6125.